Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.
Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.
ResMed Inc (ASX: RMD) is a United States based business that develops and manufactures medical devices to help people with sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed, which is short for Respiratory Medicine, was founded in 1989 by Dr Peter Farrell and now helps customers & patients in over 120 countries.
After 2018 saw the S&P/ASX 200 (INDEXASX:XJO) drop by 6.9%, investors were offered some relief in January with the market rebounding to finish the month 4.25% higher.
The ResMed Inc (ASX:RMD) share price is down another 9.2% so far today, but there are reasons to remain positive about the healthcare business.
The ResMed Inc (ASX:RMD) share price is down nearly 11% after announcing its result for the second quarter of FY19.
Australia’s share market, or the All Ordinaries Index (INDEXASX:XAO)(ASX: XAO), is currently up 0.40% at lunch.
This week, ResMed Inc. (ASX:RMD) announced it will be acquiring MatrixCare for US$750 million.
Australia’s share market, or the All Ordinaries Index (INDEXASX:XAO)(ASX:XAO), is currently up 0.24% at lunch.
ResMed Inc (ASX:RMD) has reported its result for the first quarter of the 2019 financial year.
Here are the stories from the S&P/ASX 200 (INDEXASX:XJO)(ASX:XJO) and Australian finance circles on Friday.
Australia’s share market, or the All Ordinaries Index (INDEXASX:XAO)(ASX:XAO), is currently up 0.34% at lunch.
